CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma

Su, Min-Cheng; Hsu, Chiun; Kao, Hsin-Lien; Jeng, Yung‐Ming

doi:10.1016/j.canlet.2005.03.059

Cited by 48 publications

(41 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…102 Moreover, in esophageal squamous cell carcinoma, CD24 expression correlates with tumor lymph node metastasis, tumor grade and survival time. 88 Similar observations were found in many types of cancer, including cholangiocarcinoma, 90,91 urothelial carcinoma, 93,94 ovarian cancer 95 and prostate carcinomas. 99 Consistent with a causative role for CD24 in cancer pathogenesis, small-interfering RNA silencing of tumor cell CD24 expression had a direct effect on tumor cell proliferation and survival in tissue culture.…”

Section: Cd24 In Cancer Cellssupporting

confidence: 68%

CD24: from A to Z

et al. 2010

View full text Add to dashboard Cite

As a testament to the importance of CD24, researchers with diverse interests, including adaptive immunity, inflammation, autoimmune diseases and cancer, have encountered CD24. CD24 is overexpressed in many cancers and appears oncogenic. In the adaptive immune response, CD24 is a redundant costimulatory molecule in costimulation-rich lymphoid organs but is essential in selected target organs tested, such as brain and skin. More recent studies suggest it may have a role in discriminating danger and pathogen-associated molecular patterns by dendritic cells. The biology of CD24 is intriguing but poorly understood. Here we summarize the major findings associated with CD24 to stimulate new ideas for further research that may reveal the underlying link among the diverse processes mediated by CD24.

show abstract

Section: Cd24 In Cancer Cellssupporting

confidence: 68%

CD24: from A to Z

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Despite the high frequency (60-80%) of EGFR expression in HCC, EGFR mutation in exons 18-21 is not detected (Su et al, 2006) or rare (p1%) (Wellcome Trust, 2008). However, the elevated expression of TGF-a reported in preneoplastic HCC (Feitelson et al, 2004) and as a ligand of the EGFR may indicate a role for EGFR signaling during early HCC.…”

Section: Egfr Igf and Hgf/c-met Signalingmentioning

confidence: 99%

The role of signaling pathways in the development and treatment of hepatocellular carcinoma

2010

View full text Add to dashboard Cite

“…CD24 CD24, which is also known as heat-stable antigen (HSA), is a cell adhesion molecule that is associated with morphogenic processes, cell motility, and invasive cancer cell growth [25]. CD24 has been shown to be expressed in 51-82 % of cholangiocarcinoma tissues [26,27]. The median survival for patients with high CD24 expression was shorter than that for patients with low expression [28].…”

Section: Hepatic Stem Cellmentioning

confidence: 99%

Recent advances in cancer stem cell research for cholangiocarcinoma

Kokuryo

Yokoyama

Nagino

2012

J Hepato Biliary Pancreat

View full text Add to dashboard Cite

Cancer stem cells have been identified as cells with the capacity to self‐renew and differentiate into multiple lineages of human malignancies. Cholangiocarcinoma is one of the most difficult intra‐abdominal malignancies that can be treated using a surgical approach. Chemotherapy in addition to surgery is necessary to improve patient survival. However, its clinical benefit is limited, and, to date, no other effective anticancer drug is available for this disease. Several reports have shown the existence of cholangiocarcinoma stem cells. Cell surface antigens such as CD133, CD24, EpCAM, CD44, and others have been used to isolate cholangiocarcinoma stem cells. In general, enhanced expression of these markers in resected specimens of cholangiocarcinoma was associated with malignant potential. Distinct and specific pathways are expected to be present in cancer stem cells compared to other cancer cells that have no stem cell properties. To date, reports showing possible signaling pathways in cholangiocarcinoma stem cells are limited. More research is anticipated. Targeting therapies for surface molecular markers or specific signaling pathways of cholangiocarcinoma stem cells may be important in order to change the clinical outcome of patients with this disease. However, no clinical trial has been performed so far. This review will focus on the markers and signaling pathways used to define cholangiocarcinoma stem cells. A novel therapeutic approach of targeting cholangiocarcinoma stem cells will also be discussed.

show abstract

CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma

Cited by 48 publications

References 21 publications

CD24: from A to Z

CD24: from A to Z

The role of signaling pathways in the development and treatment of hepatocellular carcinoma

Recent advances in cancer stem cell research for cholangiocarcinoma

Contact Info

Product

Resources

About